MA46440A - Solvate de diméthylsulfoxyde n-(3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl)- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2 - Google Patents

Solvate de diméthylsulfoxyde n-(3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl)- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2

Info

Publication number
MA46440A
MA46440A MA046440A MA46440A MA46440A MA 46440 A MA46440 A MA 46440A MA 046440 A MA046440 A MA 046440A MA 46440 A MA46440 A MA 46440A MA 46440 A MA46440 A MA 46440A
Authority
MA
Morocco
Prior art keywords
iodophenylamino
trioxo
mek1
cyclopropanecarboxamide
pyrido
Prior art date
Application number
MA046440A
Other languages
English (en)
Other versions
MA46440B1 (fr
Inventor
Mikhail Airatovich Chafeev
Vasily Gennadievich Ignatiev
Alexandre Vasilievich Ivachtchenko
Alexey Evgenievich Repik
Original Assignee
R Pharm Joint Stock Company R Pharm Jsc
Alexey Evgenievich Repik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Pharm Joint Stock Company R Pharm Jsc, Alexey Evgenievich Repik filed Critical R Pharm Joint Stock Company R Pharm Jsc
Publication of MA46440A publication Critical patent/MA46440A/fr
Publication of MA46440B1 publication Critical patent/MA46440B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA46440A 2016-10-10 2016-12-12 Solvate de diméthylsulfoxyde n-(3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl)- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2 MA46440B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2016139641A RU2627692C1 (ru) 2016-10-10 2016-10-10 N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
PCT/RU2016/000862 WO2018070900A1 (fr) 2016-10-10 2016-12-12 Solvate de diméthylsulfoxyde n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl}- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2

Publications (2)

Publication Number Publication Date
MA46440A true MA46440A (fr) 2021-06-02
MA46440B1 MA46440B1 (fr) 2021-11-30

Family

ID=59641667

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46440A MA46440B1 (fr) 2016-10-10 2016-12-12 Solvate de diméthylsulfoxyde n-(3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl)- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2

Country Status (28)

Country Link
US (1) US10738049B2 (fr)
EP (1) EP3524601B1 (fr)
JP (1) JP6909299B2 (fr)
KR (1) KR102387288B1 (fr)
CN (1) CN110012668B (fr)
AU (1) AU2016426350B2 (fr)
BR (1) BR112019007223A2 (fr)
CA (1) CA3039524A1 (fr)
CO (1) CO2019004688A2 (fr)
CY (1) CY1125283T1 (fr)
DK (1) DK3524601T3 (fr)
EA (1) EA037939B1 (fr)
ES (1) ES2898026T3 (fr)
HR (1) HRP20211693T1 (fr)
HU (1) HUE056490T2 (fr)
LT (1) LT3524601T (fr)
MA (1) MA46440B1 (fr)
MD (1) MD3524601T2 (fr)
MX (1) MX388031B (fr)
PH (1) PH12019500721A1 (fr)
PL (1) PL3524601T3 (fr)
PT (1) PT3524601T (fr)
RS (1) RS62604B1 (fr)
RU (1) RU2627692C1 (fr)
SI (1) SI3524601T1 (fr)
SM (1) SMT202100633T1 (fr)
WO (1) WO2018070900A1 (fr)
ZA (1) ZA201902861B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024011403A (es) 2022-03-17 2024-09-23 Springworks Therapeutics Inc Tratamiento con mirdametinib.
CN114853754B (zh) * 2022-05-23 2023-04-18 云白药征武科技(上海)有限公司 一种硫代酰胺衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
KR100883289B1 (ko) * 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
JP2016503399A (ja) * 2012-10-25 2016-02-04 ノバルティス アーゲー 組合せ
RU2605400C1 (ru) * 2015-11-13 2016-12-20 ЗАО "Р-Фарм" ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2

Also Published As

Publication number Publication date
US20190233415A1 (en) 2019-08-01
RU2627692C1 (ru) 2017-08-10
PL3524601T3 (pl) 2022-03-21
AU2016426350B2 (en) 2020-08-27
CO2019004688A2 (es) 2019-05-21
SMT202100633T1 (it) 2022-01-10
ZA201902861B (en) 2021-06-30
US10738049B2 (en) 2020-08-11
WO2018070900A1 (fr) 2018-04-19
KR20190062512A (ko) 2019-06-05
RS62604B1 (sr) 2021-12-31
CN110012668B (zh) 2021-11-26
EP3524601A1 (fr) 2019-08-14
JP6909299B2 (ja) 2021-07-28
EP3524601A4 (fr) 2020-03-11
AU2016426350A1 (en) 2019-05-30
ES2898026T3 (es) 2022-03-03
HRP20211693T1 (hr) 2022-02-04
PH12019500721A1 (en) 2019-12-02
LT3524601T (lt) 2021-12-27
PT3524601T (pt) 2021-11-03
JP2019531350A (ja) 2019-10-31
MA46440B1 (fr) 2021-11-30
MX388031B (es) 2025-03-19
EA201900158A1 (ru) 2019-08-30
CY1125283T1 (el) 2023-03-24
DK3524601T3 (da) 2021-11-08
BR112019007223A2 (pt) 2019-07-02
CA3039524A1 (fr) 2018-04-19
MX2019004137A (es) 2019-09-26
CN110012668A (zh) 2019-07-12
MD3524601T2 (ro) 2022-02-28
HUE056490T2 (hu) 2022-02-28
KR102387288B1 (ko) 2022-04-14
EA037939B1 (ru) 2021-06-09
SI3524601T1 (sl) 2022-02-28
EP3524601B1 (fr) 2021-10-13

Similar Documents

Publication Publication Date Title
DK3551753T3 (da) Diagnostik baseret på crispr-effektorsystem
AU2016327051B2 (en) Image analysis for making animal measurements including 3-D image analysis
EP3436524A4 (fr) Structures de polymère fluoré imprimées en 3-d
DK3436461T3 (da) Pyrrolotriazinforbindelser som tam-inhibitorer
EP3482719A4 (fr) Dispositif de réparation du sacrum.
HUE061575T2 (hu) Eljárások és eszközök analitikai mérés elvégzéséhez
PT3274469T (pt) Métodos para a deteção de um contaminante biológico
EP3481314A4 (fr) Dispositif de réparation de la paroi thoracique.
EP3126893A4 (fr) Mesures de mise au point par métrologie de diffusiomètrie
EP3340968A4 (fr) Comprimés implantables à base de naltrexone
EP3347562A4 (fr) Multi-conducteur à connexion filetée rapide
HUE050320T2 (hu) PDE1 inhibitor 1,5-dihidro-4H-pirazolo[3-4-d]pirimidin-4-onok és 1,5-dihidro-4H-pirazolo[3-4-d]piridin-4-onok
EP3589850C0 (fr) Plaque d'écrou à ressort
EP3352796A4 (fr) Formulation médicamenteuse à base de particules comprenant un conjugué polysaccharide-vitamine
DK3282240T3 (da) Lejeprøvestand
PL3452428T3 (pl) Preparat chemii budowlanej
FR3006437B1 (fr) Procede de calibration autonome d'un equipement inertiel utilise en mode statique
PT3689332T (pt) Formulação que compreende glicopirrolato, método e equipamento
EP3485877A4 (fr) Granule à libération prolongée avec du chlorhydrate de tamsulosine.
MA49708A (fr) Dérivés de dihétérocycle liés à cycloalkyle
BR112016025075A2 (pt) formulação agroquímica.
DK3558394T3 (da) Tetraazabicyklo-macrocykel-baseret mangan-chelatforbindelser egnede som mri-kontraststoffer
EP3524601A4 (fr) Solvate de diméthylsulfoxyde n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl}- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2
EP3517246A4 (fr) Clé à cliquet à douille universelle
EP3332237A4 (fr) Dispositif de déclenchement à double axe pour essai de pneu